Bristol-Myers to collaborate on immuno-oncology studies

Bristol-Myers Squibb ($BMY) has signed on Northwestern University to partner on some early-stage immunotherapy trials. Bristol-Myers, one of the leaders in the immuno-oncology field, will collaborate with Lurie Cancer Center and NMDTI on new studies related to small, genetically defined patient subpopulations. "Complementing our broad research and development programs through innovative collaborations with partners such as the Lurie Cancer Center and NMDTI has been a fundamental component to our commitment to leading advances in Immuno-Oncology," said Dr. Laura Bessen, head of U.S. Medical, Bristol-Myers Squibb. Release

Suggested Articles

In a pandemic world, the biotech funding environment couldn’t look brighter, and today Pfizer shone its own light.

Gilead is tapping long-term Stanford University researcher Mark Genovese, M.D., to lead its NASH, fibrosis and arthritis pipeline programs.

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…